Life Sciences Immunology Therapeutics sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Immunology Therapeutics
1.1 - About Life Sciences Immunology Therapeutics sector
Companies in Life Sciences Immunology Therapeutics research, engineer, and manufacture immune‑modulating medicines and enabling platforms for autoimmune, allergy, infectious disease, and oncology. Strategic buyers in immunology range from antibody and cell therapy developers to plasma biologics and vaccine providers. Offerings pair therapies with proprietary discovery and manufacturing technologies, delivering targeted mechanisms, scalable production, and clinically validated approaches that improve patient outcomes and accelerate development from lab to clinic.
Typical capabilities include monoclonal antibody discovery and optimization, CAR‑T and other cell therapy development, and plasma fractionation to produce immunoglobulins and related biologics. Vendors also provide allergen immunotherapy vaccines and veterinary/clinical diagnostic extracts, live biotherapeutic candidates from characterized strains, and DNA/antibody engineering toolkits. Many operate decentralized or automated manufacturing systems, cold chain and processing robotics, and translational platforms that integrate preclinical modeling, Phase I–III trial execution, and regulatory support for rare and immune-mediated diseases.
They serve hospital systems and specialty clinics, biopharma R&D partners, and academic research centers. Outcomes include faster time‑to‑IND and market through integrated platforms, improved response rates via precision immune modulation, lower production costs and supply risk with scalable manufacturing, and broader access through near‑patient cell therapy delivery and standardized allergy immunotherapy. Payers and providers see more predictable efficacy and higher treatment adherence.
2. Buyers in the Life Sciences Immunology Therapeutics sector
2.1 Top strategic acquirers of Life Sciences Immunology Therapeutics companies
Grifols
- Description: Provider of diagnostic laboratory support and service solutions, delivering equipment installation, setup, repairs, 24-hour technical assistance and user training to keep laboratory instruments running, automate workflows, reduce downtime and enable timely, high-quality patient test results.
- Key Products:
- Plasma-derived Therapies: Essential biopharmaceutical medicines produced from human plasma to treat chronic, rare and life-threatening disorders in immunology, hepatology, pulmonology and other areas
- ABO® Automated Bottle Opener: Robotic system that thaws, opens and empties frozen plasma bottles, preventing contamination, protecting worker safety and accelerating plasma fractionation workflows
- PBO® Automated Bag Opener: Machine that automatically opens and drains frozen plasma bags through controlled thawing and robotic handling, improving efficiency and product integrity during fractionation
- Clinical Diagnostics Solutions: Blood typing and clinical diagnostic platforms that deliver accurate laboratory results and support transfusion medicine, enhancing patient care and enabling healthcare providers to manage testing efficiently.
- Rationale: Provider of plasma-derived therapies for immunology, ABO Automated Bottle Opener for fractionation, and PBO Automated Bag Opener for plasma processing.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Immunology Therapeutics sector
M&A buyer group 1: Immunotherapy
Precigen
- Type: N/A
- Employees: ●●●●●
- Description: Provider of biotechnology solutions focused on human gene therapy and gene editing, leveraging proprietary DNA-engineering technologies to control cellular functions and develop treatments such as CAR-T therapies for acute myeloid leukemia.
- Key Products:
- PRGN-3006 CAR-T Therapy: Investigational CAR-T treatment granted orphan drug status targeting acute myeloid leukemia by genetically engineering patient T-cells to attack cancer cells and potentially improve clinical outcomes
- Proprietary DNA Engineering Platform: Suite of complementary technologies that enables precise DNA-based control over cellular functions, supporting creation of diverse gene and cell therapies
- Human Gene Editing Programs: Focused research initiatives applying advanced gene-editing techniques to develop next-generation therapeutics for multiple diseases using Precigen’s engineered cell and gene platforms
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Immunology Therapeutics sector
3.1 - Buyout funds in the Life Sciences Immunology Therapeutics sector
2.2 - Strategic buyer groups for Life Sciences Immunology Therapeutics sector
4 - Top valuation comps for Life Sciences Immunology Therapeutics companies
4.2 - Public trading comparable groups for Life Sciences Immunology Therapeutics sector
Valuation benchmark group 1: Monoclonal Antibody Drug Developers
Eli Lilly
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of innovative medicines and biotechnology solutions aimed at improving global health. Utilizes advanced scientific research and development to create treatments for various medical conditions, enhancing quality of life and addressing unmet clinical needs in diverse healthcare areas.
- Key Products:
- Insulin Access Programs: Solutions to provide accessible insulin treatments for diabetes management.
- Cancer Treatments: Medicines targeted at oncology to improve patient outcomes.
- Cardiovascular Treatments: Innovative treatments for heart-related conditions.
- Immunology: Solutions addressing autoimmune diseases and enhancing immune system health.
- Neuroscience: Medications to treat neurological disorders including Alzheimer's and schizophrenia.